Cline Christopher R. bought TVTX
April 13, 2026 · Form 4 insider transaction
Cline Christopher R. bought 14,000 shares of Travere Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
14,000
Price
$0.00
Total value
N/A
InsiderCline Christopher R.
RoleOfficer
SecurityCommon Stock
Transaction codeA: Grant or award
Transaction dateApril 13, 2026
Filing dateApril 15, 2026
Shares owned after125,226
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.